← Leaderboard
SRPT
Ticker
SRPT
Congressional Trades
1
by 1 members
Ticker Intelligence Brief
Who in Congress traded SRPT, when, and what happened after?
A ticker-first view for retail/data users: latest disclosure, largest range, disclosure lag, party flow, contracts, lobbying, and source-linked receipts.
Latest receipt
Gilbert Cisneros
SELL · 2025-04-14
Largest range
$1K – $15K
Gilbert Cisneros
Slowest filing
22d
Gilbert Cisneros
Best vs SPY
-94.2%
Gilbert Cisneros
Buys
0
0%
Sells
1
100%
Total Volume
$8K
midpoint
Unique Traders
1
members
Party Breakdown
Democrats1 · 100%
Republicans0 · 0%
💼 Lobbying Filings
all →- 2026-04-20$270KSAREPTA THERAPEUTICS INC.Duchenne Muscular Dystrophy and Rare Disease Patient Access to Treatments Newborn Screening for Rare Diseases Scientific Innovation in Healthcare Gene Therapies Artificial Intelligence and Data Governance
- 2026-04-20$110KSAREPTA THERAPEUTICSScientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy
- 2026-04-20$90KSAREPTA THERAPEUTICSfederal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting
- 2026-01-20$230KSAREPTA THERAPEUTICS INC.Patient Access to Treatments Newborn Screening for Rare Diseases Scientific Innovation in Healthcare Gene Therapies Rare Diseases Artificial Intelligence and Data Governance
- 2026-01-20$110KSAREPTA THERAPEUTICSScientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy
- 2026-01-20$90KSAREPTA THERAPEUTICSfederal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting
- 2025-10-20$110KSAREPTA THERAPEUTICSScientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy
- 2025-10-20$80KSAREPTA THERAPEUTICSfederal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid value based payment rule
- 2025-10-15$430KSAREPTA THERAPEUTICS INC.Issues related to patient access to treatments Issues related to rare diseases such as Duchenne Muscular Dystrophy Issues related to newborn screening for rare diseases Issues related to the Inflation Reduction Act's prescription drug provisions Issues related to scientific innovation in healthcare such as gene therapies Issues related to artificial intelligence and data governance Tax issues related to research and development
- 2025-07-21$80KSAREPTA THERAPEUTICSfederal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid value based payment rule
Congressional Momentum
buy vs. sell pressureDISTRIBUTINGScore 0–100: above 50 = net buying pressure, below 50 = net selling. Signal based on last 90 days.
Last 30 Days
No trades
Last 90 Days
No trades
All-Time
▼0
0 buys1 total1 sell
$0 buys · $8K sells
All Disclosed Trades
| Date | Member | Action | Amount | Filing Delay | Receipt |
|---|---|---|---|---|---|
| 2025-04-14 | DGilbert Cisneros | SELL | $1K – $15K | 22d | receipt → |